Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “neutral” rating reissued by research analysts at J P Morgan Chase & Co in a research note issued on Thursday, July 6th. They presently have a $10.00 target price on the specialty pharmaceutical company’s stock. J P Morgan Chase & Co’s target price would indicate a potential downside of 35.28% from the company’s previous close.

VRX has been the subject of a number of other research reports. BidaskClub cut Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research report on Friday, June 16th. Scotiabank reduced their price target on Valeant Pharmaceuticals International from $15.00 to $12.00 and set a “sector perform” rating for the company in a research report on Wednesday, April 26th. Vetr lowered Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.82 price objective on the stock. in a research note on Monday, May 22nd. Wells Fargo & Company restated an “underperform” rating and set a $10.00 price target (down from $11.00) on shares of Valeant Pharmaceuticals International in a research note on Tuesday, March 14th. They noted that the move was a valuation call. Finally, Mizuho restated an “underperform” rating and set a $8.00 price target (down from $9.00) on shares of Valeant Pharmaceuticals International in a research note on Monday, April 17th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals International has a consensus rating of “Hold” and an average target price of $16.96.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded down 2.298% during midday trading on Thursday, reaching $15.095. The company’s stock had a trading volume of 17,469,956 shares. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $32.75. The stock has a 50-day moving average price of $16.16 and a 200 day moving average price of $13.34. The stock’s market capitalization is $5.25 billion. Valeant Pharmaceuticals International also was the recipient of some unusual options trading on Thursday. Stock traders purchased 16,974 put options on the company. This is an increase of approximately 100% compared to the average daily volume of 8,473 put options.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.93. The firm had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $2.17 billion. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The business’s revenue for the quarter was down 11.1% on a year-over-year basis. During the same quarter last year, the firm earned ($1.08) earnings per share. Equities analysts forecast that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/04/valeant-pharmaceuticals-international-inc-vrx-stock-rating-reaffirmed-by-j-p-morgan-chase-co-updated-updated-updated.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 20,000 shares of the firm’s stock in a transaction dated Thursday, May 11th. The stock was bought at an average cost of $13.90 per share, with a total value of $278,000.00. Following the completion of the transaction, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.87% of the company’s stock.

Several hedge funds have recently made changes to their positions in VRX. Gruss & Co. Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 223.4% in the second quarter. Gruss & Co. Inc. now owns 30,400 shares of the specialty pharmaceutical company’s stock worth $526,000 after buying an additional 21,000 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Valeant Pharmaceuticals International during the second quarter worth approximately $1,597,000. BB&T Securities LLC raised its position in shares of Valeant Pharmaceuticals International by 14.5% in the second quarter. BB&T Securities LLC now owns 40,797 shares of the specialty pharmaceutical company’s stock worth $705,000 after buying an additional 5,165 shares during the last quarter. Blair William & Co. IL raised its position in shares of Valeant Pharmaceuticals International by 58.4% in the second quarter. Blair William & Co. IL now owns 72,866 shares of the specialty pharmaceutical company’s stock worth $1,261,000 after buying an additional 26,865 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Valeant Pharmaceuticals International by 9.2% in the second quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock worth $23,895,000 after buying an additional 121,032 shares during the last quarter. Institutional investors own 50.53% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.